Tradestie Institutional Equity Comparison Engine

CGEM vs CRMD โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CRMD Overall Edge

CRMD Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CorMedix Inc. (CRMD) driven by superior Valuation, Growth & Margin while CGEM counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, CGEM trades at 6.7x Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus CRMD at 29.5x Forward P/E and 41.0% operating margin (-47.7% YoY). In options structure, CGEM sits in UNCLASSIFIED (9th %ile IV; Dealer Gamma Walls on Pro) against CRMD sits in BREAKDOWN (90th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CRMD
CGEM 6.7x vs CRMD 29.5x Fwd P/E
Growth & Margin Winner CRMD
Op Margin 0.0% vs 41.0% ยท YoY +0.0% vs -47.7%
Momentum & Technical Winner CGEM
1Y +8.5% vs -58.5% ยท 52W Pos 9% vs 0%
Options & Structure Winner CGEM
UNCLASSIFIED (9th %ile IV) vs BREAKDOWN (90th %ile IV)
CGEM NASDAQ
Cullinan Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$9.28
-2.37% 1D
Market Cap $667.4M
1M Return -33.66%
1Y Return +8.48%
Forward P/E 6.7x
Unified AI Score
40.9 / 100 SELL
Tech 25.0 Fund 43.0 Flow 50.0 Mom 59.0
CRMD NASDAQ
CorMedix Inc.
Pharmaceutical Preparations
$4.67
-3.11% 1D
Market Cap $370.6M
1M Return -36.72%
1Y Return -58.45%
Forward P/E 29.5x
Unified AI Score
55.5 / 100 HOLD
Tech 60.0 Fund 62.0 Flow 70.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CGEM +8.48% CRMD -58.45% Spread: +66.93 pp (CGEM Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CGEM TTM Op. Margin: 0.0% CRMD TTM Op. Margin: 41.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CGEM vs CRMD. Trailing 12-month operating profitability (CGEM 0.0% vs CRMD 41.0%) and valuation multiples (CGEM 6.7x vs CRMD 29.5x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CGEM (4) vs CRMD (6)
Institutional Metric CGEM CRMD Criterion Row Winner
Market Capitalization Scale $667.4M $370.6M Larger Scale CGEM
Trailing P/E Ratio Valuation 6.7x 2.4x Lower Multiple CRMD
Forward P/E Ratio Valuation 6.7x 29.5x Lower Multiple CGEM
Revenue Growth (YoY) Growth +0.0% -47.7% Higher Growth CGEM
Operating Margin (TTM) Profitability 0.0% 41.0% Higher Margin CRMD
Net Profit Margin Profitability 0.0% 15.5% Higher Margin CRMD
Return on Equity (ROE) Capital Efficiency -55.5% 15.3% Higher ROE CRMD
52-Week Range Position Momentum 9% ($8โ€“$23) 0% ($5โ€“$13) Stronger Trend CGEM
Beta / 30D Volatility Risk Regime 1.63ฮฒ ยท 104% Vol 1.22ฮฒ ยท 103% Vol Lower Realized Risk CRMD
Unified Institutional Score Composite Signal 40.9 / 100 (SELL) 55.5 / 100 (HOLD) Higher Composite CRMD

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CGEM vs CRMD Buy Guide
CGEM UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 9th %ile
IV Regime Compressed (<25th %ile)
Live CGEM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CRMD BREAKDOWN
110d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 90th %ile
IV Regime Extreme (>80th %ile)
Live CRMD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CGEM nor CRMD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.